Lipase Inhibitor Use for Extracellular Aging-Related Tissue Damage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Aging is associated with chronic low-grade inflammation and autodigestion due to compromised mucin/epithelial barriers, leading to cellular damage and organ dysfunction, with lipases contributing to this process outside the gastrointestinal tract.
Innovation Solution
Administering a therapeutically effective amount of a lipase inhibitor, such as tetrahydrolipstatin or nafamostat mesylate, to subjects at risk of or experiencing lipase accumulation in organs, thereby reversing cellular damage and reducing lipase activity outside the GI tract.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If lipase inhibitor is administered to reduce lipase activity outside GI tract, then cellular damage and inflammation are reduced, but digestive enzyme activity in GI tract may be affected
Solution Approach 1:
The patent applies local quality by using lipase inhibitors with different spatial distributions and tissue penetration characteristics. Some inhibitors are designed to act primarily in extracellular spaces while having limited intracellular penetration, allowing selective inhibition of extracellular lipase activity in target organs while preserving intracellular digestive functions in the GI tract.
Solution Approach 2:
The patent employs delivery systems and carrier molecules as intermediaries to transport lipase inhibitors selectively to target organs. These intermediaries facilitate the inhibitor's passage through biological barriers to reach extracellular compartments in specific tissues while minimizing exposure to and inhibition of digestive enzymes in the GI tract.
2Object-affected harmful factors
If broad-spectrum lipase inhibitor is used to block all lipase activity, then inflammation is reduced, but nutrient absorption is impaired
Solution Approach 1:
The patent applies partial action by using inhibitors that selectively block lipase activity in specific pathological contexts (extracellular accumulation in target organs) while allowing sufficient lipase activity to remain in the GI tract for normal lipid digestion and nutrient absorption. The inhibition is tuned to be sufficient to reduce inflammation but not so strong as to impair digestive function.
Solution Approach 2:
The patent employs parameter changes by modifying inhibitor properties such as molecular weight, charge, and hydrophobicity to control tissue distribution and enzyme specificity. These parameter adjustments allow the inhibitor to preferentially bind to extracellular lipases in target organs while having reduced affinity for intracellular digestive lipases, thereby reducing inflammation without significantly impacting nutrient absorption.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively reduces lipase activity and cellular damage in organs, ameliorating age-related conditions and diseases by blocking lipase activity outside the gastrointestinal tract, thus improving organ function and reducing inflammation.
Implementation Method 1
administering a therapeutically effective amount of a lipase inhibitor, such as tetrahydrolipstatin or nafamostat mesylate, to subjects at risk of or experiencing lipase accumulation in organs, thereby reversing cellular damage and reducing lipase activity outside the GI tract
Data Source
AI summary
Provided herein are methods of general biological aging in a subject, including, but not limited to specific presentations of biological aging such as mild cognitive impairment, dementia, unstable blood pressure, collagen degradation, insulin-receptor cleavage, type 2 diabetes, kidney, lung, or intestine degradation which include administering the subject a therapeutically effective amount of a lipase inhibitor.